https://www.selleckchem.com/pr....oducts/epacadostat-i
The optimal antithrombotic regimen after transcatheter aortic valve replacement remains unclear. In this randomized open-label study, low-risk patients undergoing transfemoral transcatheter aortic valve replacement at 7 centers in the United States were randomized 11 to low-dose aspirin or warfarin plus low-dose aspirin for 30 days. Patients who could not be randomized were enrolled in a separate registry. Computed tomography or transesophageal echocardiography was performed at 30 days. The primary effectiveness end point
Me gusta
Comentario
Compartir
